Gold coated lanthanide phosphate nanoparticles for targeted radiotherapy by Sobol, Nicholas, 1988-
Gold-Coated Lanthanide Phosphate Nanoparticles for Targeted Radiotherapy 
Nicholas Sobol 
Dr. J.D. Robertson, Dissertation Advisor 
 
Abstract 
The success of a targeted radiotherapy system depends on its ability to carry and deliver 
its radioactive payload to a specific site.  Lanthanide phosphate nanoparticles are highly stable in 
a variety of solvents.  By conjugating different sized polyethylene glyclol (PEG) linkers to the 
gold-surface of the nanoparticles it is possible to alter the in vivo biodistribution.  The 
nanoparticles are synthesized by the co-crystallization of orthophosphate and lanthanide metal 
ions and gold-coated by reduction of NaAuCl4 with sodium citrate.  The nanoparticles retain 
>95% of the 177Lu after two weeks in milli-Q water, phosphate buffered saline, and fetal bovine 
serum.  The ability to adjust the biodistribution has been demonstrated by altering the PEG 
length from 800 Da to 5000 Da and the utilization of clodronate liposomes in a murine model.  
Eighty-five percent of the injected dose (ID) of nanoconjugates with the 800 Da PEG linker 
accumulated in the lung in 1 hour and 55% ID remained in the lung 24 hours post injection in 
clodronate treated mice. Control mice showed 50% ID in the lung at 1 hour and 24 hours post 
injection. Approximately fifty percent ID of the 5000 Da labeled nanoconjugate accumulated in 
the lung in 1 hour in both control and clodronate treated mice. These values dropped to 30% and 
13% at 24 hours in clodronate and control mice, respectively.    Future experiments will target 
nanoparticles specifically to cancer cells using antibodies in a murine model of metastatic lung 
disease. 
